Global patterns of drug allergy-induced fatalities: a wake-up call to prevent avoidable deaths.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
ppublish
Résumé
To identify patterns and key issues though a systematic review in order to support prevention strategies and reduce avoidable deaths related to drug-induced anaphylaxis (DAF). DAF rate has been estimated by 0.13-0.53/106 population/year. General global trends of DAF are increasing over time, mostly occurring at healthcare settings (62%) with a similar gender distribution and an average age of 53 years. Antibiotics, anaesthetics, radio-contrast media and NSAIDs were the most frequently implicated agents. Main comorbidities were personal history of drug allergy, cardiovascular diseases and asthma. Main manifestations were cardiovascular and respiratory commitments. Use of adrenaline is mentioned in only 29% of the articles. DAF is increasing worldwide and most cases are iatrogenic. This first systematic review of DAF identified key gaps and served as a wake-up call to prevent avoidable deaths. Phenotype at risk for DAF was represented by patients aged more than 54 years, with personal history of drug allergy/hypersensitivity with no or incomplete allergological work-up, cardiovascular disease and/or asthma with need of hospitalization and/or frequent healthcare assistance. Additional risk for those who need frequent use of intravenous antibiotics and/or undergoing surgery or image investigation with radiocontrast media.
Identifiants
pubmed: 35852895
doi: 10.1097/ACI.0000000000000835
pii: 00130832-202208000-00003
doi:
Substances chimiques
Anti-Bacterial Agents
0
Contrast Media
0
Epinephrine
YKH834O4BH
Types de publication
Journal Article
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
215-220Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Wheatley LM, Plaut M, Schwaninger JM, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. J Allergy Clin Immunol 2015; 136:262–271.
Pouessel G, Lejeune S, Deschildre A, et al. Mortalité par anaphylaxie en France métropolitaine: analyse des données nationales de 1979 à 2011. Revue Francaise d’Allergologie 2017; 57:525–532.
Kleinrock M, Muñoz E. Global medicine spending and usage trends: outlook to 2024. IQVIA Institute for Human Data Science. 2020. pp. 1–26.
Pumphrey RSH, Roberts ISD. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 2000; 53:273.
Jerschow EMDM, Lin RYMDM, Scaperotti MMBS, et al. Fatal anaphylaxis in the United States, 1999–2010: Temporal patterns and demographic associations. J Allergy Clin Immunol 2014; 134:1318–1328.
Liew WK, Williamson E, Tang MLK. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol 2009; 123:434–442.
Tanno LK, Demoly P. Allergy in the World Health Organization's International Classification of Diseases (ICD)-11. Pediatr Allergy Immunol 2022; 33 (S27):5–7.
Xu YS, Kastner M, Harada L, et al. Anaphylaxis-related deaths in Ontario: a retrospective review of cases from 1986 to 2011. Asthma Clin Immunol 2014; 10:38.
Mullins RJ, Wainstein BK, Barnes EH, et al. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp Allergy 2016; 46:1099–1110.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372:71.
James LP, Austen KF. Fatal systemic anaphylaxis in man. New Engl J Med 1964; 270:597–603.
Delage C, Irey NS. Anaphylactic deaths: a clinicopathologic study of 43 cases. J Forensic Sci 1972; 17:525–540.
Yunginger JW, Nelson DR, Squillace DL, et al. Laboratory investigation of deaths due to anaphylaxis. J Forensic Sci 1991; 36:857–865.
Lenler-Petersen P, Hansen D, Andersen M, et al. Drug-related fatal anaphylactic shock in Denmark 1968–1990. A study based on notifications to the Committee on Adverse Drug Reactions. J Clin Epidemiol 1995; 48:1185–1188.
Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144–1150.
Low I, Stables S. Anaphylactic deaths in Auckland, New Zealand: a review of coronial autopsies from 1985 to 2005. Pathology 2006; 38:328–332.
Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunology 2007; 98:252–257.
Shen Y, Li L, Grant J, et al. Anaphylactic deaths in Maryland (United States) and Shanghai (China): a review of forensic autopsy cases from 2004 to 2006. Forensic Sci Int 2009; 186:1–5.
Simon MR, Mulla ZD. A population-based epidemiologic analysis of deaths from anaphylaxis in Florida. Allergy 2008; 63:1077–1083.
Yilmaz R, Yuksekbas O, Erkol Z, et al. Postmortem findings after anaphylactic reactions to drugs in Turkey. Am J Forensic Med Pathol 2009; 30:346–349.
Tanno LK, Ganem F, Demoly P, et al. Undernotification of anaphylaxis deaths in Brazil due to difficult coding under the ICD-10. Allergy 2012; 67:783–789.
Ma LP, Danoff TMMDP, Borish LMD. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol 2014; 133:1075–1083.
Turner PJFP, Gowland MHBA, Sharma VF, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992–2012. J Allergy Clin Immunol 2015; 135:956–963.
Tanno LK, Bierrenbach AL, Calderon MA, et al. Decreasing the undernotification of anaphylaxis deaths in Brazil through the International Classification of Diseases (ICD)-11 revision. Allergy 2017; 72:120–125.
Tejedor-Alonso MA, Martínez-Fernandez P, Vallejo-de-Torres G, et al. Clinical and demographic characteristics of fatal anaphylaxis in Spain (1998–2011): a comparison between a series from the hospital system and a national forensic series. Clin Exp Allergy 2019; 49:82–91.
Turner PJ, Campbell DE, Motosue MS, et al. Global trends in anaphylaxis epidemiology and clinical implications. J Allergy Clin Immunol Pract 2020; 8:1169–1176.
Tanno LK, Chalmers R, Jacob R, et al. Global implementation of the world health organization's International Classification of Diseases (ICD)-11: the allergic and hypersensitivity conditions model. Allergy 2020; 75:2206–2218.
Tanno LK, Chalmers R, Bierrenbach AL, et al. Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases-11. J Allergy Clin Immunol 2019; 144:627–633.
Turner PJ, Worm M, Ansotegui IJ, et al. Time to revisit the definition and clinical criteria for anaphylaxis? World Allergy Organization J 2019; 12:100066.
Regateiro FS, Marques ML, Gomes ER. Drug-induced anaphylaxis: an update on epidemiology and risk factors. Int Arch Allergy Immunol 2020; 181:481–487.
Nassiri MMS, Babina MP, Dölle SP, et al. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol 2015; 135:491–499.
Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001; 87:177–180.
Tanno LK, Simons FE, Annesi-Maesano I, et al. Fatal anaphylaxis registries data support changes in the who anaphylaxis mortality coding rules. Orphanet J Rare Dis 2017; 12:8.